Citadel Advisors
APRE icon

Citadel Advisors’s Aprea Therapeutics APRE Stock Holding History

Citadel Advisors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47K Buy
+58,600
New +$48.9K ﹤0.01% 13143
2026
Q1 		– Sell
-51,041
Closed -$43.5K – 12922
2025
Q4 		$43.5K Buy
+51,041
New +$62.7K ﹤0.01% 12095
2025
Q2 		– Sell
-30,083
Closed -$61.4K – 12423
2025
Q1 		$61.4K Buy
+30,083
New +$94.2K ﹤0.01% 12088
2023
Q1 		– Sell
-64
Closed -$411 – 14668
2022
Q4 		$411 Buy
+64
New +$675 ﹤0.01% 14664
2022
Q3 		– Sell
-944
Closed -$16.8K – 12543
2022
Q2 		$14K Sell
944
-2,910
-76% -$67.1K ﹤0.01% 12509
2022
Q1 		$143K Sell
3,854
-4,309
-53% -$177K ﹤0.01% 11903
2021
Q4 		$469K Buy
8,163
+2,066
+34% +$183K ﹤0.01% 9858
2021
Q3 		$623K Buy
6,097
+4,666
+326% +$424K ﹤0.01% 9335
2021
Q2 		$140K Buy
+1,431
New +$132K ﹤0.01% 12565
2020
Q4 		– Sell
-3,704
Closed -$1.78M – 10873
2020
Q3 		$1.78M Sell
3,704
-11,743
-76% -$6.57M ﹤0.01% 4925
2020
Q2 		$12M Sell
15,447
-615
-4% -$404K ﹤0.01% 2021
2020
Q1 		$11.2M Buy
16,062
+611
+4% +$448K 0.01% 1742
2019
Q4 		$14.2M Buy
+15,451
New +$8.51M 0.01% 1837

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's APRE Position: Q2 2026 in Review

Citadel Advisors opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 58,600 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #13143 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in APRE as recently as Q4 2025.

Citadel Advisors first reported a position in APRE in Q4 2019 and has held it in 13 quarters since. The position peaked at $14.2M in Q4 2019. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Citadel Advisors held 58,600 shares of Aprea Therapeutics worth $47K as of Q2 2026.
  • Aprea Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Aprea Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13143 holding.
  • Citadel Advisors first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • Citadel Advisors's Aprea Therapeutics position peaked at $14.2M in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.